Invasive and noninvasive cardiac-specific biomarkers, along with modifiable and nonmodifiable risk factors, provide valuable insights into the pathophysiology and early prevention of CVD in obesity.
Understanding invasive and noninvasive cardiac-specific biomarkers and risk factors may yield valuable insights into the pathophysiology and early prevention of CVD in high-risk obese populations.
Cardiovascular disease (CVD) is the leading cause of fatality and disability worldwide regardless of gender. Obesity has reached epidemic proportions in population across different regions. According to epidemiological studies, CVD risk markers in childhood obesity are one of the significant risk factors for adulthood CVD, but have received disproportionally little attention. This review has examined the evidence for the presence of traditional cardiac biomarkers (nonspecific; lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, creatine kinase, myoglobulin, glycogen phosphorylase isoenzyme BB, myosin light chains, ST2, and ischemia-modified albumin) and novel emerging cardiac-specific biomarkers (cardiac troponins, natriuretic peptides, heart-type fatty acid-binding protein, and miRNAs). Besides, noninvasive anatomical and electrophysiological markers (carotid intima-media thickness, coronary artery calcification, and heart rate variability) in CVDs and obesity are also discussed. Modifiable and nonmodifiable risk factors associated with metabolic syndrome in the progression of CVD, such as obesity, diabetes, hypertension, dyslipidemia, oxidative stress, inflammation, and adipocytokines are also outlined. These underlying prognostic risk factors predict the onset of future microvascular and macrovascular complications. The understanding of invasive and noninvasive cardiac-specific biomarkers and the risk factors may yield valuable insights into the pathophysiology and prevention of CVD in a high-risk obese population at an early stage.
Parsanathan et al. (Wed,) conducted a review in Obesity and Cardiovascular Diseases. Cardiac-specific biomarkers was evaluated. Invasive and noninvasive cardiac-specific biomarkers, along with modifiable and nonmodifiable risk factors, provide valuable insights into the pathophysiology and early prevention of CVD in obesity.